Q1 Earnings Forecast for TRDA Issued By William Blair

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for shares of Entrada Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.73) for the quarter. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. William Blair also issued estimates for Entrada Therapeutics’ Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.81) EPS and Q4 2026 earnings at ($0.86) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.69. The business had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.

Other equities research analysts have also issued reports about the company. Oppenheimer lifted their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. Roth Mkm initiated coverage on Entrada Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price objective on the stock. Roth Capital upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday, February 25th.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $10.99 on Monday. The firm has a market cap of $411.25 million, a P/E ratio of 6.91 and a beta of -0.17. Entrada Therapeutics has a fifty-two week low of $10.80 and a fifty-two week high of $21.79. The business’s 50 day moving average price is $14.06 and its 200-day moving average price is $16.18.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its stake in Entrada Therapeutics by 21.6% during the fourth quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company’s stock valued at $36,011,000 after buying an additional 368,908 shares during the last quarter. Vanguard Group Inc. raised its stake in Entrada Therapeutics by 19.7% during the fourth quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company’s stock valued at $25,317,000 after buying an additional 241,052 shares during the last quarter. Geode Capital Management LLC raised its stake in Entrada Therapeutics by 8.8% during the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after buying an additional 46,512 shares during the last quarter. State Street Corp raised its stake in Entrada Therapeutics by 5.5% during the third quarter. State Street Corp now owns 469,601 shares of the company’s stock valued at $7,504,000 after buying an additional 24,385 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Entrada Therapeutics by 28.5% during the fourth quarter. Northern Trust Corp now owns 318,177 shares of the company’s stock valued at $5,501,000 after buying an additional 70,497 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Insider Activity

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of Entrada Therapeutics stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total transaction of $476,359.95. Following the completion of the transaction, the insider now owns 4,402,849 shares in the company, valued at approximately $91,447,173.73. The trade was a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.59% of the stock is currently owned by company insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.